Tenderwize
Zurück zur Suche

Open-House Discount Agreement Trastuzumab - Regions Lower Saxony, Bremen and Saxony-Anhalt

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Apr 21, 2027 · 239 days left·Open·Supplies·Framework
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Trastuzumab, ATC L01FD01 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

No estimated value or guaranteed volume; contracts may be automatically suspended if another discount contract is signe...

Strict paper submission with hand signatures and required authorization documents; errors could invalidate offer.

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive discount agreements for Trastuzumab (ATC L01FD01) parenteral preparations in oncology for direct medical application to patients.
  • Two regional lots: Lower Saxony/Bremen and Saxony-Anhalt.
Vollständige Zusammenfassung anzeigen

Open-house non-exclusive discount agreement for the active substance Trastuzumab (ATC L01FD01) for parenteral preparations in oncology, for the regions of Lower Saxony/Bremen (Lot 1) and Saxony-Anhalt (Lot 2). This is not a competitive procurement but a voluntary open-house model where all eligible pharmaceutical entrepreneurs can join identical, non-negotiable contracts. Contracts run from 1 July 2025 to 30 June 2027. No estimated value is provided.

Risiken

No estimated value or guaranteed volume; contracts may be automatically suspended if another discount contract is signe...

Strict paper submission with hand signatures and required authorization documents; errors could invalidate offer.

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG (German Medicines Act).
  • Company seat must be in Germany, EU, or EEA (§ 9 Abs. 2 AMG).

Administrative

  • Submission in paper form (two signed originals) plus electronic spreadsheet via email.

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

Award criterion is price (weight not specified).

Auftraggeber

Lose (1)

LOT-0000

Open-House Discount Agreement Trastuzumab - Regions Lower Saxony, Bremen and Saxony-Anhalt

Two regional sub-lots: Regionallos 1 (Niedersachsen/Bremen) and Regionallos 2 (Sachsen-Anhalt). All eligible pharmaceutical entrepreneurs may conclude identical non-exclusive discount agreements for Trastuzumab parenteral preparations.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE929, Germany

Dauer

Jun 2025 - Jun 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

Price

Frist

Deadline Apr 21, 2027

Vergabedetails

Veröffentlichungsdatum
27 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
271454-2025

Ähnliche Ausschreibungen